The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections

References

• Casadevall A, Cassone A, Bistoni F, et al. Antibody and/or cell-mediated immunity, protective mechanisms in fungal dis-ease: an ongoing dilemma or an unnecessary dispute? Med Mycol 1998; 36 (Suppl. 1): 95–105.
   Google Scholar
• Levitz SM. Overview of host defenses in fungal infections. Clin Infect Dis 1992; 36 (Suppl. 1): S37–S42.
   Google Scholar
• Romani L, Howard DH. Mechanisms of resistance to fungal infections. Curr Opin Immunol 1995; 7: 517–523.
   Google Scholar
• Casadevall A. Antibody immunity and invasive fungal infec-tions. Infect Immun 1995; 63: 4211–4218.
   PubMed Web of Science ®Google Scholar
• Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987; 55: 749–752.
   Google Scholar
• Mukherjee J, Scharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Im-mun 1992; 60: 4534–4541.
   Google Scholar
• Yuan R, Casadevall A, Spira G, Scharff MD. Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to Cryptococcus neoformans into a protective antibody. J Im-munol 1995; 154: 1810-1816.
   Google Scholar
• Yuan R, Spira G, Oh J, Paizi M, Casadevall A, Scharff MD. Isotype switching increases antibody protective efficacy to Cryptococcus neoformans infection in mice. Infect Immun 1998; 66: 1057–1062.
   PubMed Web of Science ®Google Scholar
• Dromer F, Salamero J, Contrepois A, Carbon C, Yeni P. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neofor-mans capsular polysaccharide. Infect Immun 1987; 55: 742–748.
   Google Scholar
• Mukherjee J, Nussbaum G, Scharff MD, Casadevall A. Protec-tive and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J Exp Med 1995; 181: 405–409.
   PubMed Web of Science ®Google Scholar
• Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect Immun 1995; 63: 2714–2719.
   PubMed Web of Science ®Google Scholar
• Casadevall A. Antibody immunity and Cryptococcus neofor-mans. Can J Bot 1995; 40: 888–892.
   Google Scholar
• Pirofski L, Casadevall A. Antibody immunity to Cryptococcus neoformans: Paradigm for antibody immunity to the fungi? Zbl Bakt 1996; 284: 475–495.
   PubMedGoogle Scholar
• Vecchiarelli A, Casadevall A. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res Immunol 1998; 149: 321–333.
   PubMedGoogle Scholar
• Deepe GS Jr. Prospects for the development of fungal vaccines. Gun Microbiol Rev 1997; 10: 585–596.
   PubMed Web of Science ®Google Scholar
• Dixon DM, Casadevall A, Klein B, Mendoza L, Travassos LR, Deepe G. Development of vaccines and their use in the preven-tion of fungal infections. Med Mycol 1998; 36 (Suppl. 1): 57–67.
   Google Scholar
• Odds FC. Candida and candidosis. London: Bailliere Tindall, 1988.
   Google Scholar
• Banerjee U, Mohapatra LN, Kumar R. Role of antibody in defence against murine candidosis. Indian J Med Res 1984; 79: 760–765.
   Google Scholar
• Hector RF, Domer JE, Carrow EW. Immune responses to Candida albicans in genetically distinct mice. Infect Immun 1982; 3& 1020–1028.
   Google Scholar
• Wagner RD, Vazquez-Torres A, Jones-Carson J, Warner T, Balish E. B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis. J Infect Dis 1996; 174: 589–597.
   PubMedGoogle Scholar
• Berger M, Kirkpatrick CH, Goldsmith PK, Gallin JI. IgE antibodies to Staphylococcus aureus and Candida albicans in patients with the syndrome of hyperimmunoglobulin E and recurrent infections. J Immunol 1980; 125: 2437–2443.
   PubMedGoogle Scholar
• van Deventer AJ, Goessens WH, van Zeijl JH, Mouton JW, Michel MF, Verbrugh HA. Kinetics of anti-mannan antibodies useful in confirming invasive candidiasis in immunocompro-mised patients. Microbiol Immunol 1996; 40: 125–131.
   PubMedGoogle Scholar
• Mourad S, Friedman L. Active immunization against Candida albicans. Proc Soc Exp Biol Med 1961; 106: 570–572.
   PubMedGoogle Scholar
• Mourad S, Friedman L. Passive immunization of mice against Candida albicans. Sabouraudia 1968; 6: 103–105.
   PubMedGoogle Scholar
• Cassone A, Boccanera M, Adriani DA, Santoni G, De Bemardis F. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vagi-nal infection. Infect Immun 1995; 63: 2619–2624.
   Google Scholar
• Costantino PJ, Franklyn KM, Gare NF, Warmington JR. Production of antibodies to antigens of Candida albicans in CBA/H mice. Infect Immun 1994; 62: 1400–1405.
   PubMed Web of Science ®Google Scholar
• Matthews RC. Pathogenicity determinants of Candida albicans: potential targets for immunotherapy? Microbiology 1994; 140: 1505–1511.
   PubMed Web of Science ®Google Scholar
• Tavares D, Ferreira P, Vilanova M, Videira A, Arala-Chaves M. Immunoprotection against systemic candidiasis in mice. Int Immunol 1995; 7: 785–796.
   Google Scholar
• Cassone A, Conti S, De Bemardis F, Polonelli L. Antibod-ies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol Today 1997; 18: 164–169.
   Google Scholar
• Kanbe T, Han Y, Redgrave B, Riesselman MH, Cutler JE. Evidence that mannans of Candida albicans are responsible for adherence of yeast forms to spleen and lymph node tissue. Infect Immun 1993; 61: 2578–2584.
   Google Scholar
• Kanbe T, Cutler JE. Minimum chemical requirements for ad-hesin activity of the acid-stable part of Candida albicans cell wall phosphomannoprotein complex. Infect Immun 1998; 66: 5812–5818.
   PubMed Web of Science ®Google Scholar
• Li RK, Cutler JE. Chemical definition of an epitope/adhesin molecule on Candida albicans. J Biol Chem 1993; 268: 18293–18299.
   PubMedGoogle Scholar
• Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998; 66: 5771–5776.
   Google Scholar
• Han Y, Kanbe T, Chemiak R, Cutler JE. Biochemical charac-terization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun 1997; 65: 4100–4107.
   PubMed Web of Science ®Google Scholar
• Shibata N, Ikuta K, Imai T, et al. Existence of branched side chains in the cell wall mannan of pathogenic yeast, Candida albicans. Structure-antigenicity relationship between the cell wall mannans of Candida albicans and Candida parapsilosis. J Biol Chem 1995; 270: 1113–1122.
   Google Scholar
• Han Y, Riesselman MH, Cutler JE. Protection against can-didiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective anti-body. Infect Immun 2000; 68: 1649–1654.
   Google Scholar
• Feldmesser M, Casadevall A. Effect of serum IgG1 to Crypto-coccus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol 1997; 158: 790–799.
   PubMed Web of Science ®Google Scholar
• Nussbaum G, Cleare W, Casadevall A, Scharff MD, Valadon P. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med 1997; 185: 685–697. @ 2000 ISHAM, Medicd Mycology, 38, Suppl. 1,281-292
   Google Scholar
• Han Y, Ulrich MA, Cutler JE. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis 1999; 179: 1477–1484.
   Google Scholar
• Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992; 14: S148–S153.
   Google Scholar
• Fidel PL Jr, Sobel JD. Immunopathogenesis of recurrent vulvo-vaginal candidiasis. Gun Microbiol Rev 1996; 9: 335–348.
   Google Scholar
• De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G, Cassone A. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997; 65: 3399–3405.
   PubMed Web of Science ®Google Scholar
• Rogers TJ, Balish E. Immunity to Candida albicans. Microbiol Rev 1980; 44: 660–682.
   PubMedGoogle Scholar
• Stencel C. Experts probe complexity of Candida. ASM News 1999; 65: 542–546.
   Google Scholar
• Matthews RC, Burnie JP, Smith D, et al. Candida and AIDS: evidence for protective antibody. fancet 1988; ii: 263–266.
   Google Scholar
• Matthews RC, Burnie JP. Antibodies and Candida: potential therapeutics. Trends Microbiol 1996; 4: 354–358.
   PubMedGoogle Scholar
• Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21: 150–161.
   PubMed Web of Science ®Google Scholar
• Casadevall A. Passive antibody therapies: progress and continu-ing challenges. Clin Immunol 1999; 93: 5–15.
   PubMed Web of Science ®Google Scholar
• Begent RH, Verhaar MJ, Chester KA, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996; 9: 979–984.
   Google Scholar
• Matthews RC, Bumie JP, Tabaqchali S. Immunoblot analysis of the serological response in systemic candidosis. Lancet 1984; ii: 1415–1418.
   Google Scholar
• Matthews RC, Bumie JP. Cloning of a DNA sequence encod-ing a major fragment of the 47 kilodalton stress protein homo-logue of Candida albicans. FEMS Microbiol Lett 1989; 60: 25–30.
   Web of Science ®Google Scholar
• Matthews RC, Bumie JP, Howat D, Rowland T, Walton F. Autoantibody to heat shock protein 90 can mediate protection against systemic candidosis. Immunology 1991; 74: 20–24.
   Google Scholar
• Matthews RC, Hodgetts S, Burnie J. Preliminary assessment of a human recombinant antibody fragment to hsp90 in the treat-ment of murine invasive candidiasis. J Infect Dis 1995; 171: 1668–1771.
   Google Scholar
• Gomez FJ, Allendoerfer R, Deepe GS Jr. Vaccination with recombinant heat shock protein 60 from Histoplasma capsula-turn protects mice against pulmonary histoplasmosis. Infect Immun 1995; 63: 2587–2595.
   Google Scholar
• Polonelli L, Morace G. Production and characterization of yeast killer toxin monoclonal antibodies. J Gun Microbiol 1987; 25: 460–462.
   Google Scholar
• Polonelli L, Conti S, Gerloni M, et al. `Antibiobodies': antibi-otic-like anti-idiotypic antibodies. J Med Vet Mycol 1991; 29: 235–242.
   PubMedGoogle Scholar
• Polonelli L, Lorenzini R, De Bemardis F, et al. Idiotypic vaccination: immunoprotection mediated by anti-idiotypic anti-bodies with antibiotic activity. Scan J Immuno11993; 37: 105–110.
   PubMed Web of Science ®Google Scholar
• Polonelli L, De Bemardis F, Boccanera M, et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol 1994; 152: 3175–3181.
   PubMed Web of Science ®Google Scholar
• Polonelli L, De Bemardis F, Conti S, et al. Human natural yeast killer toxin-like candidacidal antibodies. J Immunol 1996; 156: 1880–1885.
   PubMed Web of Science ®Google Scholar
• Seguy N, Cailliez JC, Delcourt P, et al. Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii. Mol Med 1997; 3: 544–552.
   PubMed Web of Science ®Google Scholar
• Conti S, Fanti F, Magliani W, et al. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. J Infect Dis 1998; 177: 807–811.
   PubMedGoogle Scholar
• Polonelli L, Seguy N, Conti S, et al. Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin Diagn Lab Immunol 1997; 4: 142–146.
   PubMedGoogle Scholar
• Seguy N, Polonelli L, Dei-Cas E, Cailliez JC. Monoclonal killer toxin-like antiidiotypic antibodies to control rat-pneumocysto-sis. J Eulcaryot Microbiol 1997; 44: 37S.
   Google Scholar
• Magliani W, Conti S, De Bemardis F, et al. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity [see comments]. Nat Biotechnol 1997; 15: 155–158.
   PubMedGoogle Scholar
• Smith CE, Whiting EG, Baker EE, et al. The use of coccid-ioidin. Am Rev Tuberculosis 1948; 57: 330–351.
   PubMedGoogle Scholar
• Beaman L, Pappagianis D, Benjamini E. Significance of T cells in resistance to experimental murine coccidioidomycosis. Infect Immun 1977; 17: 580–585.
   PubMedGoogle Scholar
• Beaman L, Pappagianis D, Benjamini E. Mechanisms of resis-tance to infection with Coccidioides immitis in mice. Infect Immun 1979; 23: 681–685.
   Google Scholar
• Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13: 151–177.
   PubMed Web of Science ®Google Scholar
• Magee DM, Cox RA. Interleukin-12 regulation of host defenses against Coccidioides immitis. Infect Immun 1996; 64:3609–3613.
   PubMed Web of Science ®Google Scholar
• Fierer J, Walls L, Eckmann L, Yamamoto T, Kirkland TN. Importance of interleukin-10 in genetic susceptibility of mice to Coccidioides immitis. Infect Immun 1998; 66: 4397–4402.
   Google Scholar
• Levine HB, Cobb JM, Smith CE. Immunogenicity of spherule-endospore vaccines of Coccidioides immitis for mice. J Immunol 1961; 87: 218–227.
   Google Scholar
• Pappagianis D. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am Rev Respir Dis 1993; 148: 656–660.
   PubMed Web of Science ®Google Scholar
• Zimmermann CR, Johnson SM, Martens GW, White AG, Zimmer BL, Pappagianis D. Protection against lethal murine coccidioidomycosis by a soluble vaccine from spherules. Infect Immun 1998; 66: 2342–2345.
   PubMedGoogle Scholar
• Lecara G, Cox RA, Simpson RB. Coccidioides immitis vaccine: potential of an alkali-soluble, water-soluble cell wall antigen. Infect Immun 1983; 39: 473–475.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yang C, Magee DM, Cox RA. Molecular cloning and characterization of Coccidioides immitis antigen 2 cDNA. Infect Immun 1996; 64: 2695–2699.
   PubMed Web of Science ®Google Scholar
• Huppert M, Spratt NS, Vukovich KR, Sun SH, Rice EH. Antigenic analysis of coccidioidin and spherulin determined by two-dimensional immunoelectrophoresis. Infect Immun 1978; 20: 541–551.
   Google Scholar
• Dugger KO, Villareal KM, Ngyuen A, Zimmermann CR, Law JH, Galgiani JN. Cloning and sequence analysis of the cDNA for a protein from Coccidioides immitis with immunogenic potential. Biochem Biophys Res Commun 1996; 218: 485–489.
   PubMedGoogle Scholar
• au Y, Yang C, Magee DM, Cox RA. Coccidioides immitis antigen 2: analysis of gene and protein. Gene 1996; 181: 121–125.
   PubMedGoogle Scholar
• Kirkland TN, Finley F, Orsborn KI, Galgiani JN. Evaluation of the proline-rich antigen of Coccidioides immitis as a vaccine candidate in mice. Infect Immun 1998; 66: 3519–3522.
   PubMed Web of Science ®Google Scholar
• Jiang C, Magee DM, Quitugua TN, Cox RA. Genetic vaccina-tion against Coccidioides immitis: comparison of vaccine effi-cacy of recombinant antigen 2 and antigen 2 cDNA Infect Immun 1999; 67: 630–635.
   Google Scholar
• Abuodeh RO, Shubitz LF, Siegel E, et al. Resistance to Cocci-dioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. Infect Immun 1999; 67: 2935–2940.
   PubMed Web of Science ®Google Scholar
• Cole GT, Kirkland TN, Franco M, et al. Immunoreactivity of a surface wall fraction produced by spherules of Coccidioides immitis. Infect Inman 1988; 56: 2695–2701.
   PubMed Web of Science ®Google Scholar
• Kirkland TN, Thomas PW, Finley F, Cole GT. Immunogenic-ity of a 48-kilodalton recombinant T-cell-reactive protein of Coccidioides immitis. Infect Immun 1998; 66: 424–431.
   PubMed Web of Science ®Google Scholar
• Hung CY, Ampel NM, Christian L, Seshan KR, Cole GT. A major cell surface antigen of Coccidioides immitis which elicits both humoral and cellular immune responses. Infect Immun 2000; 6& 584–593.
   Google Scholar
• Kirkland TN, Zhu SW, Kruse D, Hsu LL, Seshan KR, Cole GT. Coccidioides immitis fractions which are antigenic for immune T lymphocytes. Infect Immun 1991; 59: 3952–3961.
   PubMedGoogle Scholar
• Morris JA, Domer Al, Edwards CA, Hendershot LM, Kauf-man RJ. Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins. J Biol Chem 1997; 272: 4327–4334.
   Google Scholar
• Casadevall A, Cleare W, Feldmesser M, et al. Characterization of a murine monoclonal antibody to Cryptocococcus neofor-mans polysaccharide that is a candidate for human thera-peutic studies. Antimicrob Agents Chemother 1998; 42: 1437–1446.
   PubMed Web of Science ®Google Scholar